نتائج البحث

Ixabepilone to Treat Cervical Cancer

• Authors : Antonio Fojo, M.D., Principal Investigator

• Source: A Phase II Clinical Trial of Ixabepilone (Ixempra [R], BMS-247550, NSC 710428), an Epothilone B Analog, in Cervical CancerParkin DM, Laara E, Muir CS. Estimates of the worldwide frequency of

تفاصيل العنوان

Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research Protocols

• Source: Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute (NCI) Clinical Research Protocols

تفاصيل العنوان

Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer

• Authors : Ravi A. Madan, M.D., Principal Investigator

• Source: A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC/TRICOM and Flutamide vs. Flutamide Alone in Men With Androgen Insensitive, Non-Metastatic (D0.5) Prostate CancerJemal A,

تفاصيل العنوان

BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer

• Authors : Alice Chen, M.D., Principal Investigator

• Source: A Phase II Study of BAY 43-9006 (Sorafenib) in Combination With Cetuximab (Erbitux ) in EGFR Expressing Metastatic Colorectal Cancer (CRC)Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H,

تفاصيل العنوان

MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma

• Authors : Shivaani Kummar, M.D., Principal Investigator

• Source: Pilot Study of the Combination of MK-2206, an AKT Inhibitor, and AZD6244, a MEK Inhibitor, in Patients With Advanced Colorectal CarcinomaMessa C, Russo F, Caruso MG, Di Leo A. EGF, TGF-alpha,

تفاصيل العنوان

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes

• Authors : Steven A. Rosenberg, M.D./National Cancer Institute

• Source: Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-gp100:154-162 TCR-Gene Engineered LymphocytesKawakami Y, Eliyahu S, Delgado CH, Robbins PF,

تفاصيل العنوان

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes

• Authors : Steven A. Rosenberg, M.D./National Cancer Institute

• Source: Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 F5 TCR-Gene Engineered LymphocytesKawakami Y, Eliyahu S, Delgado CH, Robbins PF,

تفاصيل العنوان